ArticleFrontiers in endocrinology2025
Intelligent prediction of thyroid cancer in China based on GBD data and hospital electronic medical records: disease burden analysis combined with multiple machine learning models.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to conduct an in-depth analysis of the disease burden pattern and future trends of thyroid cancer in China, and constructed an intelligent prediction model in combination with hospital electronic medical record data. It comprehensively reveals the disease burden trend of thyroid cancer in China, predicts the mortality rate of thyroid cancer in China, and emphasizes the causal role of high BMI as an important controllable risk factor. And provided a high-precision prediction model for benign and malignant thyroid cancer. The results show that the prevalence of thyroid cancer in China has shown a significant upward trend from 1990 to 2021, especially among women, and the peak age of onset has shifted later. The mortality rate of men is on the rise, while that of women is on the decline. The risk of thyroid cancer mortality caused by high BMI significantly increases during this period, and MR analysis confirms that high BMI increases the risk of thyroid cancer. The ARIMA model predicts that the prevalence of thyroid cancer in China will continue to increase in the next ten years, while the mortality rate will remain relatively stable. Among the machine learning models, XGBoost achieved the highest predictive accuracy and identified BMI as the most influential clinical feature in distinguishing between benign and malignant thyroid tumors. This study provides a solid scientific basis for the development of more accurate and effective strategies for the prevention, early diagnosis, and management of thyroid cancer in China and even globally, and provides a feasible path for the use of artificial intelligence assisted diagnosis in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.